Paper35565263
Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma.
Wach J and 5 others. Cancers (Basel), 2022. Cited by 5 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma. Papers, record 35565263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35565263
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25978009 | A meta-analysis: Do prophylactic antiepileptic drugs in patients with brain tumors decrease the incidence of seizures? | Clin Neurol Neurosurg | 2015 | https://conductscience.org/library/papers/25978009 | PubMed |
| 2 | 22748650 | Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). | Neurosurg Clin N Am | 2012 | https://conductscience.org/library/papers/22748650 | PubMed |
| 3 | 33024247 | Benefits of glioma resection in the corpus callosum. | Sci Rep | 2020 | https://conductscience.org/library/papers/33024247 | PubMed |
| 4 | 31192128 | The Role of 5-ALA in Low-Grade Gliomas and the Influence of Antiepileptic Drugs on Intraoperative Fluorescence. | Front Oncol | 2019 | https://conductscience.org/library/papers/31192128 | PubMed |
| 5 | 26366972 | The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors. | Neurosurgery | 2016 | https://conductscience.org/library/papers/26366972 | PubMed |
| 6 | 25032543 | 3.0-T intraoperative magnetic resonance imaging-guided resection in cerebral glioma surgery: interim analysis of a prospective, randomized, triple-blind, parallel-controlled trial. | Neurosurgery | 2014 | https://conductscience.org/library/papers/25032543 | PubMed |
| 7 | 26544781 | A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. | J Neurosurg | 2016 | https://conductscience.org/library/papers/26544781 | PubMed |
| 8 | 21438658 | Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. | J Neurosurg | 2011 | https://conductscience.org/library/papers/21438658 | PubMed |
| 9 | 18667747 | Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. | Neuro Oncol | 2008 | https://conductscience.org/library/papers/18667747 | PubMed |
| 10 | 31332208 | Effects of 5-aminolevulinic acid and sodium ferrous citrate on fibroblasts from individuals with mitochondrial diseases. | Sci Rep | 2019 | https://conductscience.org/library/papers/31332208 | PubMed |
| 11 | 19937366 | The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. | J Neurooncol | 2010 | https://conductscience.org/library/papers/19937366 | PubMed |
| 12 | 16648043 | Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. | Lancet Oncol | 2006 | https://conductscience.org/library/papers/16648043 | PubMed |
| 13 | 30018520 | Glioblastoma in Patients over 70 Years of Age. | Radiol Oncol | 2018 | https://conductscience.org/library/papers/30018520 | PubMed |
| 14 | 18981880 | Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. | Neurosurgery | 2008 | https://conductscience.org/library/papers/18981880 | PubMed |
| 15 | 33735464 | First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. | Epilepsia | 2021 | https://conductscience.org/library/papers/33735464 | PubMed |
| 16 | 32612203 | Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy. | Sci Rep | 2020 | https://conductscience.org/library/papers/32612203 | PubMed |
| 17 | 15279715 | Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. | Neuro Oncol | 2004 | https://conductscience.org/library/papers/15279715 | PubMed |
| 18 | 11150363 | Brain tumors. | N Engl J Med | 2001 | https://conductscience.org/library/papers/11150363 | PubMed |
| 19 | 30790732 | Correlation of Ki-67 Index with Volumetric Segmentation and its Value as a Prognostic Marker in Glioblastoma. | World Neurosurg | 2019 | https://conductscience.org/library/papers/30790732 | PubMed |
| 20 | 33747971 | Baseline Serum C-Reactive Protein and Plasma Fibrinogen-Based Score in the Prediction of Survival in Glioblastoma. | Front Oncol | 2021 | https://conductscience.org/library/papers/33747971 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39653818 | Impact of levetiracetam use in glioblastoma: an individual patient-level meta-analysis assessing overall survival. | Neurosurg Rev | 2024 | https://conductscience.org/library/papers/39653818 | PubMed |
| 37736977 | Intraoperative Fluorophores: An Update on 5-Aminolevulinic Acid and Sodium Fluorescein in Resection of Tumors of the Central Nervous System and Metastatic Lesions-A Systematic Review and Meta-Analysis. | Tomography | 2023 | https://conductscience.org/library/papers/37736977 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| FECH | 2235 | PubTator's text mining | https://conductscience.org/library/genes/2235 | NCBI Gene |
| GFAP | 2670 | PubTator's text mining | https://conductscience.org/library/genes/2670 | NCBI Gene |
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35565263
GET https://conductscience.org/api/papers/v1/35565263/references?page=2